Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-AL...

Full description

Bibliographic Details
Main Authors: Yuan Meng, Biping Deng, Luan Rong, Chuo Li, Weiliang Song, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Alex H. Chang, Xiaoming Feng, Xiujuan Xiong, Xiaoli Chen, Jing Pan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
B-NHL
CAR-T
CD19
CD22
CD20
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.640166/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.640166/full

Similar Items